The Seattle Times


Monday, November 10, 2014

Biotech’s pitfalls tripped up Dendreon, led it to bankruptcy

Dendreon manufactured its Provenge treatment for prostate cancer at this processing plant in New Jersey and two others. The Seattle company borrowed heavily to build the plants. It has since sold the New Jersey one.